DAVID MONTY BERMAN
Medical Practice in Baltimore, MD
License number
Pennsylvania MD068963L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Baltimore, MD 21211
Pennsylvania
Pennsylvania
Personal information
See more information about DAVID MONTY BERMAN at radaris.comName
Address
Phone
510 Conshohocken State Rd, Penn Valley, PA 19072
429 Fairview Rd, Elkton, MD 21921
8502 16Th St APT 203, Silver Spring, MD 20910
8314 Rising Ridge Way, Bethesda, MD 20817
8903 Danville Ter, Frederick, MD 21701
Professional information
See more information about DAVID MONTY BERMAN at trustoria.com
Vice President At A.r.g. Llc
Vice President At A.r.g. Llc
Position:
Vice President at A.R.G. LLC
Location:
Baltimore, Maryland Area
Industry:
Environmental Services
Work:
A.R.G. LLC
since Jun 2008
-
Vice President
Tricat, Inc.
Oct 1995 - May 2008
-
Chief Commercial Officer
Akzo Nobel Chemicals
Apr 1988 - Sep 1995
-
Account Manager
Filtrol
1988 - 1990
-
Account Manager
Education:
Loyola College in Maryland 1978 - 1982
MBA, Marketing University of Maryland College Park 1974 - 1978
B.S., Chemistry
MBA, Marketing University of Maryland College Park 1974 - 1978
B.S., Chemistry
Skills:
Chemicals, Catalysis, Database Management, Refining, Catalyst, Database Admin, Process Simulation, Biofuels, Process Design
Urothelial Differentiation Of Urothelial Carcinoma: A Bladder Cancer Stem Cell Model
Urothelial Differentiation Of Urothelial Carcinoma: A Bladder Cancer Stem Cell Model
US Patent:
2009004, Feb 19, 2009
Filed:
Mar 24, 2008
Appl. No.:
12/079078
Inventors:
David M. Berman - Towson MD, US
William Matsui - Baltimore MD, US
Xiaobing He - Baltimore MD, US
William Matsui - Baltimore MD, US
Xiaobing He - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 51/08, A61P 35/00, A61K 39/395, A61B 5/055, A61K 49/00, A61K 51/10
US Classification:
424 149, 4241301, 424 93, 424 96, 424 111, 4241781, 4241831
Abstract:
The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.
Social Worker At V.a. Medical Center
Social Worker At V.a. Medical Center
Position:
Social Worker at V.A. Medical Center
Location:
Baltimore, Maryland Area
Industry:
Government Administration
Work:
V.A. Medical Center
-
Social Worker
Social Worker At Department Of Veterans Affairs
Social Worker At Department Of Veterans Affairs
Position:
Social Worker at Department of Veterans Affairs
Location:
Baltimore, Maryland Area
Industry:
Government Administration
Work:
Department of Veterans Affairs
-
Social Worker
David Berman, Baltimore MD
David Berman, Baltimore MD
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287
Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
US Patent:
2008005, Mar 6, 2008
Filed:
Oct 20, 2004
Appl. No.:
10/576149
Inventors:
David N. Watkins - Baltimore MD, US
David M. Berman - Towson MD, US
Stephen B. Baylin - Baltimore MD, US
Philip A. Beachy - Towson MD, US
David M. Berman - Towson MD, US
Stephen B. Baylin - Baltimore MD, US
Philip A. Beachy - Towson MD, US
International Classification:
A61K 39/395, A61K 31/42, A61P 35/00, C12N 5/08, C12Q 1/68, G01N 33/53
US Classification:
4241581, 435375, 435 6, 435 78, 514 12, 514278
Abstract:
Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in small-cell lung cancer (SCLQ cells, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating SCLC associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of SCLC to treatment with a Hh pathway antagonist.
Dr. David M Berman, Columbia MD - MD (Doctor of Medicine)
Dr. David M Berman, Columbia MD - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
Wilmer Eye Institute
10700 Charter Dr SUITE 140, Columbia 21044
(410) 910-2330 (Phone)
10700 Charter Dr SUITE 140, Columbia 21044
(410) 910-2330 (Phone)
Languages:
English
Hospitals:
Wilmer Eye Institute
10700 Charter Dr SUITE 140, Columbia 21044
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
10700 Charter Dr SUITE 140, Columbia 21044
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
University Of Tx Southwestern Med Center At Dallas Med School
Graduated: 1996
Johns Hopkins University School Med
University Of Tx Southwestern Med Center At Dallas Med School
Graduated: 1996
Johns Hopkins University School Med
David Monty Berman, Baltimore MD
David Monty Berman, Baltimore MD
Specialties:
Pathologist
Address:
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Anatomic Pathology (Pathology)
Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
US Patent:
2008011, May 22, 2008
Filed:
Jul 15, 2004
Appl. No.:
10/564580
Inventors:
Philip A. Beachy - Towson MD, US
David Monty Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US
Anirban Maitra - Kensington MD, US
David Monty Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US
Anirban Maitra - Kensington MD, US
International Classification:
A61K 31/395, C12N 5/04, A61K 38/00, A61K 31/70, C12Q 1/20, C12Q 1/68
US Classification:
4241301, 435375, 514 2, 514 44, 435 29, 435 6
Abstract:
Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in digestive tract cancers, including esophagus, stomach, biliary tract, and pancreatic cancer, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a digestive tract cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a digestive tract tumor to treatment with an Hh pathway antagonist.
Hedgehog Signaling In Prostate Regeneration Neoplasia And Metastasis
Hedgehog Signaling In Prostate Regeneration Neoplasia And Metastasis
US Patent:
2008009, Apr 24, 2008
Filed:
Oct 1, 2004
Appl. No.:
10/572430
Inventors:
Philip A. Beachy - Towson MD, US
David M. Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US
David M. Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/395, A61K 31/4355, A61K 31/7105, C12Q 1/48, C12Q 1/68, C12Q 1/02, A61K 38/16
US Classification:
4241301, 435 15, 435 29, 435 6, 435 71, 514 12, 514278, 514 44
Abstract:
Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a prostate tumor to treatment with an Hh pathway antagonist.